Atria Investments Inc reduced its stake in shares of Chemed Co. (NYSE:CHE – Free Report) by 13.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,122 shares of the company’s stock after selling 666 shares during the period. Atria Investments Inc’s holdings in Chemed were worth $2,184,000 at the end of the most recent quarter.
Several other hedge funds also recently added to or reduced their stakes in CHE. UMB Bank n.a. grew its holdings in Chemed by 300.0% during the 4th quarter. UMB Bank n.a. now owns 52 shares of the company’s stock worth $28,000 after acquiring an additional 39 shares in the last quarter. Trust Co. of Vermont acquired a new position in Chemed during the 4th quarter worth $34,000. SRS Capital Advisors Inc. grew its holdings in Chemed by 39.2% during the 4th quarter. SRS Capital Advisors Inc. now owns 135 shares of the company’s stock worth $72,000 after acquiring an additional 38 shares in the last quarter. Allworth Financial LP grew its holdings in Chemed by 2,057.1% during the 4th quarter. Allworth Financial LP now owns 151 shares of the company’s stock worth $83,000 after acquiring an additional 144 shares in the last quarter. Finally, Farther Finance Advisors LLC grew its holdings in Chemed by 2,314.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 338 shares of the company’s stock worth $203,000 after acquiring an additional 324 shares in the last quarter. 95.85% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Separately, StockNews.com raised shares of Chemed from a “hold” rating to a “buy” rating in a report on Friday.
Insider Activity
In other news, VP Brian C. Judkins acquired 145 shares of the business’s stock in a transaction that occurred on Monday, December 30th. The shares were purchased at an average cost of $519.50 per share, for a total transaction of $75,327.50. Following the transaction, the vice president now directly owns 1,678 shares in the company, valued at $871,721. This trade represents a 9.46 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kevin J. Mcnamara sold 2,000 shares of Chemed stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $593.67, for a total transaction of $1,187,340.00. Following the completion of the sale, the chief executive officer now owns 102,679 shares in the company, valued at approximately $60,957,441.93. This represents a 1.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 3.32% of the company’s stock.
Chemed Stock Performance
NYSE CHE opened at $595.86 on Monday. Chemed Co. has a one year low of $512.12 and a one year high of $654.62. The company has a 50-day simple moving average of $553.87 and a 200-day simple moving average of $563.91. The firm has a market capitalization of $8.72 billion, a PE ratio of 30.11, a price-to-earnings-growth ratio of 2.15 and a beta of 0.43.
Chemed Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Friday, March 14th. Stockholders of record on Monday, February 24th will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 0.34%. The ex-dividend date is Monday, February 24th. Chemed’s dividend payout ratio (DPR) is presently 10.05%.
Chemed Company Profile
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
Featured Articles
- Five stocks we like better than Chemed
- Compound Interest and Why It Matters When Investing
- Institutional Investors Bet $1B on These 4 Stocks—Should You?
- How to Calculate Stock Profit
- One Must-Buy Stock and One to Avoid as Tariffs Shake the Market
- Best Stocks Under $5.00
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.